Impact of cytokine gene polymorphisms on graft-vs-host disease

Tissue Antigens

Volumn 72, Issue 6, 2008, Pages 507-516

  Markey, K A ^a,b   MacDonald, K P A ^a   Hill, G R ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cytokine effectors; Genetic polymorphisms; Graft vs host disease

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; CYTOKINE; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; LYMPHOTOXIN; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA POLYMORPHISM; DOWN REGULATION; EFFECTOR CELL; GENETIC POLYMORPHISM; GRAFT VERSUS HOST REACTION; HAPLOIDY; HOMOZYGOSITY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INNATE IMMUNITY; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NATURAL KILLER T CELL; PREDICTION; PRIORITY JOURNAL; REVIEW; TH1 CELL;

ANIMALS; CYTOKINES; GENOTYPE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KILLER CELLS, NATURAL; POLYMORPHISM, GENETIC; T-LYMPHOCYTE SUBSETS;

ANIMALIA;

EID: 55949126381     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2008.01139.x     Document Type: Review

References (102)

1. Bensinger WI, Martin PJ, Storer B et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001 : 344 : 175 81.
2. CIBMTR. Current Use and Outcome of Hematopoietic Stem Cell Transplantation 2005. Wilwaukee : Center for International Blood and Marrow Transplant Research, 2005.
3. Cooke KR. Acute lung injury after allogeneic stem cell transplantation: from the clinic, to the bench and back again. Pediatr Transplant 2005 : 9 : 25 36.
4. Burman AC, Banovic TD, Kuns RD et al. IFN{gamma} differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. Blood 2007 : 110 : 1064 72.
5. Lee SJ. New approaches for preventing and treating chronic graft-versus-host disease. Blood 2005 : 105 : 4200 6.
6. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994 : 83 : 2360 7.
7. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 1992 : 175 : 405 13.
8. Beutler B, Cerami A. The biology of cachectin/TNF-a primary mediator of the host response. Annu Rev Immunol 1989 : 7 : 625 55.
9. Hill GR, Rebel V, Teshima T et al. The p55 TNFa receptor plays a critical role in T cell alloreactivity. J Immunol 2000 : 164 : 656 63.
10. Piguet PF, Grau GE, Allet B, Vassalli PJ. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med 1987 : 166 : 1280 9.
11. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JLM. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997 : 90 : 3204 13.
12. Hill GR, Teshima T, Gerbita A et al. Differential roles of IL-1 and TNFa on graft-versus-host disease and graft-versus leukemia. J Clin Invest 1999 : 104 : 459 67.
13. Holler E, Kolb HJ, Moller A et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990 : 75 : 1011 6.
14. Levine JE, Paczesny S, Mineishi S et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008 : 111 : 2470 5.
15. Kennedy GA, Butler J, Western R, Morton J, Durrant S, Hill GR. Combination antithymocyte globulin and soluble TNF[alpha] inhibitor (etanercept) +//- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease. Bone Marrow Transplant 2006 : 37 : 1143 7.
16. Herve P, Flesch M, Tiberghien P et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992 : 81 : 1993 9.
17. Holler E, Kolb HJ, Wilmanns W. Treatment of GVHD-TNF-antibodies and related antagonists. Bone Marrow Transplant 1993 : 3 : 29 31.
18. Dickinson AM, Harrold JL, Cullup H. Haematopoietic stem cell transplantation: can our genes predict clinical outcome? Expert Rev Mol Med 2007 : 9 : 1 19.
19. Remberger M, Jaksch M, Uzunel M, Mattsson J. Serum levels of cytokines correlate to donor chimerism and acute graft-vs.-host disease after haematopoietic stem cell transplantation. Eur J Haematol 2003 : 70 : 384 91.
20. Middleton P, Taylor PA, Jackson G, Proctor SJ, Dickinson A. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood 1998 : 92 : 3943 8.
21. Nordlander A, Uzunel M, Mattsson J, Remberger M. The TNFd4 allele is correlated to moderate-to-severe acute graft-versus-host disease after allogeneic stem cell transplantation. Br J Haematol 2002 : 119 : 1133 6.
22. Socie G, Loiseau P, Tamouza R et al. Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation 2001 : 72 : 699 706.
23. Bettens F, Passweg J, Gratwohl A et al. Association of TNFd and IL-10 polymorphisms with mortality in unrelated hematopoietic stem cell transplantation. Transplantation 2006 : 81 : 1261 7.
24. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997 : 94 : 3195 9.
25. Groux H, O'Garra A, Bigler M et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997 : 389 : 737 42.
26. Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 2006 : 108 : 1435 40.
27. Taga K, Mostowski H, Tosato G. Human interleukin-10 can directly inhibit T-cell growth. Blood 1993 : 81 : 2964 71.
28. Taga K, Tosato G. IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol 1992 : 148 : 1143 8.
29. Moore KW, O'Garra AO, De Waal Malefy R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol 1993 : 11 : 165 90.
30. Krenger W, Snyder K, Smith S, Ferrara JLM. Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens. Transplantation 1994 : 58 : 1251 7.
31. Blazar BR, Taylor PA, Panoskaltsis-Mortari A et al. Interleukin-10 dose-dependent regulation of CD4+ and CD8+ T cell-mediated graft-versus-host disease. Transplantation 1998 : 66 : 1220 9.
32. Blazar BR, Taylor PA, Smith S, Vallera DA. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood 1995 : 85 : 842 51.
33. Lin MT, Storer B, Martin PJ et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 2003 : 349 : 2201 10.
34. Lin MT, Storer B, Martin PJ et al. Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor beta genotype of donor. Blood 2005 : 106 : 3995 4001.
35. Cooke KR, Ferrara JL. A protective gene for graft-versus-host disease. N Engl J Med 2003 : 349 : 2183 4.
36. Rowe V, Banovic T, Macdonald KP et al. Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood 2006 : 108 : 2485 92.
37. Abhyankar S, Gilliland DG, Ferrara JLM. Interleukin 1 is a critical effector molecule during cytokine dysregulation in graft-versus-host disease to minor histocompatibility antigens. Transplantation 1993 : 56 : 1518 23.
38. Dunn CJ. Cytokines as mediators of chronic inflammatory disease. In : Kimball ES, ed. Cytokines and Inflammation. Boca Raton : CRC Press, 1991, 1 35.
39. Hurme M, Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol 1998 : 28 : 2598 602.
40. Foxwell BMJ, Barrett K, Feldmann M. Cytokine receptors: structure and signal transduction. Clin Exp Immunol 1992 : 90 : 161 9.
41. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996 : 87 : 2095 147.
42. Colotta F, Re F, Muzio M et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993 : 261 : 472 5.
43. MacMillan ML, Radloff GA, DeFor TE, Weisdorf DJ, Davies SM. Interleukin-1 genotype and outcome of unrelated donor bone marrow transplantation. Br J Haematol 2003 : 121 : 597 604.
44. Cullup H, Dickinson AM, Cavet J, Jackson GH, Middleton PG. Polymorphisms of interleukin-1 alpha constitute independent risk factors for chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 2003 : 122 : 778 87.
45. McDowell TL, Symons JA, Ploski R, Forre O, Duff GW. A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism. Arthritis Rheum 1995 : 38 : 221 8.
46. Bailly S, Israel N, Fay M, Gougerot-Pocidalo MA, Duff GW. An intronic polymorphic repeat sequence modulates interleukin-1 alpha gene regulation. Mol Immunol 1996 : 33 : 999 1006.
47. Cullup H, Dickinson AM, Jackson GH, Taylor PR, Cavet J, Middleton PG. Donor interleukin 1 receptor antagonist genotype associated with acute graft-versus-host disease in human leucocyte antigen-matched sibling allogeneic transplants. Br J Haematol 2001 : 113 : 807 13.
48. Rocha V, Franco RF, Porcher R et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002 : 100 : 3908 18.
49. McCarthy PL, Abhyankar S, Neben S et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 1991 : 78 : 1915 8.
50. Antin JH, Weinstein HJ, Guinan EC et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 1994 : 84 : 1342 8.
51. Antin JH, Weisdorf D, Neuberg D et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 2002 : 100 : 3479 82.
52. Beutler B, van Huffel C. Unraveling function in the TNF ligand and receptor families. Science 1994 : 264 : 667 8.
53. Pravica V, Perrey C, Stevens A, Lee J-H, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-[gamma] gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-[gamma] production. Hum Immunol 2000 : 61 : 863 6.
54. Cavet J, Dickinson AM, Norden J, Taylor PR, Jackson GH, Middleton PG. Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood 2001 : 98 : 1594 600.
55. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995 : 86 : 1243 54.
56. Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science 1992 : 258 : 593 7.
57. Karabon L, Wysoczanska B, Bogunia-Kubik K, Suchnicki K, Lange A. IL-6 and IL-10 promoter gene polymorphisms of patients and donors of allogeneic sibling hematopoietic stem cell transplants associate with the risk of acute graft-versus-host disease. Hum Immunol 2005 : 66 : 700 10.
58. Fishman D, Faulds G, Jeffery R et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998 : 102 : 1369 76.
59. Kaplan MH, Sun Y-L, Hoey T, Grusby MJ. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 1996 : 382 : 174 7.
60. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998 : 70 : 83 243.
61. Kichian K, Nestel FP, Kim D, Ponka P, Lapp WS. IL-12 p40 message RNA expression in target organs during acute graft-versus-host disease. Possible involvement of IFN-gamma. J Immunol 1996 : 157 : 2851 6.
62. Dey BR, Yang YG, Szot GL, Pearson DA, Sykes M. Interleukin-12 inhibits graft-versus-host disease through an Fas- mediated mechanism associated with alterations in donor T-cell activation and expansion. Blood 1998 : 91 : 3315 22.
63. Reddy P, Teshima T, Kukuruga M et al. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J Exp Med 2001 : 194 : 1433 40.
64. Reddy P, Teshima T, Hildebrandt G et al. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood 2003 : 101 : 2877 85.
65. Mangan PR, Harrington LE, O'Quinn DB et al. Transforming growth factor-[beta] induces development of the TH17 lineage. Nature 2006 : 441 : 231 4.
66. Bettelli E, Carrier Y, Gao W et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006 : 441 : 235 8.
67. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGF[beta] in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006 : 24 : 179 89.
68. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of TH17 cells. Nature 2008 : 453 : 1051 7.
69. Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007 : 8 : 345 50.
70. Park H, Li Z, Yang XO et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005 : 6 : 1133 41.
71. McGeachy MJ, Bak-Jensen KS, Chen Y et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007 : 8 : 1390 7.
72. McGeachy MJ, Cua DJ. The link between IL-23 and Th17 cell-mediated immune pathologies. Semin Immunol 2007 : 19 : 372 6.
73. Harrington LE, Hatton RD, Mangan PR et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005 : 6 : 1123 32.
74. Becker C, Dornhoff H, Neufert C et al. Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J Immunol 2006 : 177 : 2760 4.
75. Yi T, Zhao D, Lin CL et al. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft versus host disease. Blood 2008 : 2 : 2.
76. Dong M, Blobe GC. Role of transforming growth factor-beta in hematologic malignancies. Blood 2006 : 107 : 4589 96.
77. Childs CB, Proper JA, Tucker RF, Moses HL. Serum contains a platelet-derived transforming growth factor. Proc Natl Acad Sci U S A 1982 : 79 : 5312 6.
78. Chen Z-M, O'Shaughnessy MJ, Gramaglia I et al. IL-10 and TGF-{beta} induce alloreactive CD4+CD25- T cells to acquire regulatory cell function. Blood 2003 : 101 : 5076 83.
79. Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2002 : 2 : 46 53.
80. Zeller JC, Panoskaltsis-Mortari A, Murphy WJ et al. Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta. J Immunol 1999 : 163 : 3684 91.
81. Zheng SG, Wang JH, Koss MN, Quismorio F Jr., Gray JD, Horwitz DA. CD4+ and CD8+ regulatory T cells generated ex vivo with IL-2 and TGF-beta suppress a stimulatory graft-versus-host disease with a lupus-like syndrome. J Immunol 2004 : 172 : 1531 9.
82. Banovic T, MacDonald KPA, Morris ES et al. TGF-{beta} in allogeneic stem cell transplantation: friend or foe? Blood 2005 : 106 : 2206 14.
83. Hattori H, Matsuzaki A, Suminoe A et al. Polymorphisms of transforming growth factor-beta1 and transforming growth factor-beta1 type II receptor genes are associated with acute graft-versus-host disease in children with HLA-matched sibling bone marrow transplantation. Bone Marrow Transplant 2002 : 30 : 665 71.
84. Gagne K, Brizard G, Gueglio B et al. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum Immunol 2002 : 63 : 271 80.
85. Ruggeri L, Capanni M, Casucci M et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999 : 94 : 333 9.
86. Lanier LL. NK cell receptors. Annu Rev Immunol 1998 : 16 : 359 93.
87. Boyington JC, Sun PD. A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors. Mol Immunol 2002 : 38 : 1007 21.
88. Ruggeri L, Mancusi A, Burchielli E, Aversa F, Martelli MF, Velardi A. Natural killer cell alloreactivity in allogeneic hematopoietic transplantation. Curr Opin Oncol 2007 : 19 : 142 7.
89. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002 : 295 : 2097 100.
90. Ruggeri L, Mancusi A, Capanni M et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007 : 110 : 433 40.
91. Miller JS, Cooley S, Parham P et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 2007 : 109 : 5058 61.
92. Laster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. J Immunol 1988 : 141 : 2629.
93. Zheng L, Fisher G, Miller RE, Peshon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T clls by tumour necrosis factor. Nature 1995 : 377 : 348 51.
94. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994 : 179 : 1109 18.
95. Teshima T, Ordemann R, Reddy P et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002 : 8 : 575 81.
96. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988 : 81 : 1162.
97. Le J, Vilcek J. Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab Invest 1987 : 56 : 234.
98. Barton BE, Shortall J, Jackson JV. Interleukins 6 and 11 protect mice from mortality in a staphylococcal enterotoxin-induced toxic shock model. Infection and Immunity 1996 : 64 : 714 8.
99. Kolls JK, Lindén A. Interleukin-17 Family Members and Inflammation. Immunity 2004 : 21 : 467 76.
100. Hempel L, Korholz D, Nussbaum P, Bonig H, Burdach S, Zintl F. High interleukin-10 serum levels are associated with fatal outcome in patients after bone marrow transplantation. Bone Marrow Transplant 1997 : 20 : 365 8.
101. Yang L, Anderson DE, Baecher-Allan C et al. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 2008 : 454 : 350 2.
102. Chen W, Jin W, Hardegen N et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-{beta} induction of transcription factor Foxp3. J Exp Med 2003 : 198 : 1875 86.